Why the study?
Does Tanshinone IIA prevent doxorubicin-induced cardiotoxicity in preclinical models?
Population
30 male Institute of Cancer Research mice (aged 6 weeks, weighing 25-29 g) and H9c2 rat myoblast cells.
Comparison
Tanshinone IIA + Doxorubicin in mice; Tanshinone… vs Doxorubicin alone and normal saline control.
Design
Preclinical, The mice were randomly assigned to 5 groups
Follow-up
8 days (in vivo)
Authors
Loading...
Hypothesis-generating for Tanshinone IIA cardioprotection; human trials needed before clinical consideration.
Does Tanshinone IIA prevent doxorubicin-induced cardiotoxicity in preclinical models?
Tanshinone IIA mitigates doxorubicin-induced cardiotoxicity in preclinical models by activating the Nrf2-dependent antioxidant pathway.
Guo et al. (2018) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: